Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke Health Care breaks ground on $135 million expansion of Wound Care manufacturing facility in Brunswick, Maine
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.
“This expansion is a bold step forward for Mölnlycke in the U.S. It reinforces our mission to free patients and caregivers from the burden of wounds, strengthens supply resilience, and helps us to deliver high-quality wound care solutions faster, smarter, and more sustainably,” says Zlatko Rihter, CEO of Mölnlycke. “I’m proud to mark this milestone for Mölnlycke, for Maine and for the future of MedTech.”
The expansion is part of Mölnlycke’s strategic commitment to localise production and meet growing demand from U.S. healthcare providers. The state-of-the-art facility will support Mölnlycke’s long-term sustainability goals by using renewable energy solutions, including wind and solar power, and streamlined logistics. It will also feature advanced machinery sourced from U.S. suppliers.
Over the next five years, the investment will create new job opportunities, increasing Mölnlycke’s workforce in Maine by approximately 10%, and will engage local contractors and suppliers. Mölnlycke’s ambition with the Brunswick expansion, is to enable for more patients in the U.S. to benefit from cutting-edge innovative and high-quality wound care products produced by Mölnlycke.
“Today isn’t just about breaking ground. It’s about being bold, embracing partnerships and leading with passion,” says Chris Biddle, General Manager of U.S. Manufacturing, Wound Care. “Thank you to everyone who helped bring this vision to reality. The expansion is a win for Mölnlycke, for the local community and, ultimately, for the patients we serve.”
The groundbreaking ceremony was attended by senior federal and state lawmakers, including US Senator for Maine, Angus King, and Maine Governor, Janet Mills, who offered their support for the investment.
Note to editors
More information, including press materials and multimedia assets, is available in Mölnlycke’s online media room at Media room: Mölnlycke Brunswick, Maine site expansion
For more information, please contact:
Latest news
-
Mölnlycke improves overall score in 2026 EcoVadis sustainability assessment
Mölnlycke has further strengthened its sustainability performance in the latest EcoVadis assessment, achieving a ranking in the 98th percentile.
-
Dartford and Gravesham NHS Trust adopts Steriwave to support infection prevention
Dartford and Gravesham NHS Trust in the UK has adopted Steriwave® nasal photodisinfection for elective orthopaedic surgery, working with Mölnlycke and Ondine Biomedical to strengthen its approach to surgical site infection prevention.
-
New leaders appointed for Mölnlycke Health Care
Gothenburg, Sweden. 3 November 2026. Mölnlycke® announces the appointment of Anders Andersson as Chief Executive Officer (CEO) of Mölnlycke Health Care and Fredrik Wallefors as President of Surgical, effective 1 January 2027.
-
Mölnlycke Health Care announces new partnership with DEBRA International to help advance wound care for the EB community
Mölnlycke is partnering with DEBRA International, the world’s leading epidermolysis bullosa (EB) patient advocacy network, to deepen understanding of the needs of people living with EB and help advance wound care for the global EB community.
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold Strategic Partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.